Resveratrol increases glucose induced GLP-1 secretion in mice: A mechanism which contributes to the glycemic control

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Dao, Thi Mai Anh ^a,b,c   Waget, Aurélie ^a,b   Klopp, Pascale ^a,b   Serino, Matteo ^a,b   Vachoux, Christelle ^a,b   Pechere, Laurent ^d   Drucker, Daniel J ^e   Champion, Serge ^c   Barthélemy, Sylvain ^f   Barra, Yves ^c   Burcelin, Rémy ^a,b   Sérée, Eric ^c  

^a INSERM   (France)

^b University Hospital of Toulouse   (France)

^c INSERM   (France)

^d ENTERONOVA SAS   (France)

^e MOUNT SINAI HOSPITAL   (Canada)

^f YVERY SARL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; MESSENGER RNA; PROGLUCAGON; RESVERATROL; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; ENDOCRINE SYSTEM; ENTEROENDOCRINE SYSTEM; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; IN VIVO STUDY; INFLAMMATION; INSULIN RELEASE; INTESTINE FLORA; LIPID DIET; MALE; MOUSE; NONHUMAN; PORTAL VEIN; PROTEIN SECRETION; STOMACH CONTENT; TREATMENT DURATION; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FAT INTAKE; INTESTINE; METABOLISM; METAGENOME; MICROBIOLOGY; SECRETION; TIME;

MUS; RICE STRIPE VIRUS;

ANIMALS; BLOOD GLUCOSE; DIETARY FATS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; INFLAMMATION; INTESTINES; MALE; METAGENOME; MICE; MICE, INBRED C57BL; RECEPTORS, GLUCAGON; STILBENES; TIME FACTORS;

EID: 79958110487     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020700     Document Type: Article

References (44)

1. Pickup JC, Crook MA, (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241-1248.
2. Hotamisligil GS, (2006) Inflammation and metabolic disorders. Nature 444: 860-867.
3. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808.
4. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761-1772.
5. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 1470-1481.
6. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, et al. (2002) Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 298: 779-784.
7. Maida A, Lamont BJ, Cao X, Drucker DJ, (2010) Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 54: 339-349.
8. Holst JJ, (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439.
9. Brubaker PL, (1991) Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 128: 3175-3182.
10. Gribble FM, Williams L, Simpson AK, Reimann F, (2003) A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52: 1147-1154.
11. Harikumar KB, Aggarwal BB, (2008) Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 7: 1020-1035.
12. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122.
13. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716.
14. Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC, (2001) Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. BiochemPharmacol 62: 1299-1308.
15. Manna SK, Mukhopadhyay A, Aggarwal BB, (2000) Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164: 6509-6519.
16. Argmann C, Auwerx J, (2006) Insulin secretion: SIRT4 gets in on the act. Cell 126: 837-839.
17. Ahuja N, Schwer B, Carobbio S, Waltregny D, North BJ, et al. (2007) Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J BiolChem 282: 33583-33592.
18. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, et al. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118.
19. Nayagam VM, Wang X, Tan YC, Poulsen A, Goh KC, et al. (2006) SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 11: 959-967.
20. Shi T, Wang F, Stieren E, Tong Q, (2005) SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. JBiol Chem 280: 13560-13567.
21. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim S, et al. (2007) Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 26: 1913-1923.
22. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
23. Beher D, Wu J, Cumine S, Kim KW, Lu S, et al. (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74: 619-624.
24. Khalil A, Villard P, Dao MA, Burcelin R, Champion S, et al. (2010) Polycyclic aromatic hydrocarbons potentiate high-fat diet effects on intestinal inflammation. Toxicol Lett 196: 161-167.
25. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, et al. (1999) Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56: 784-790.
26. Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, et al. (2008) Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149: 4768-4777.
27. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, et al. (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50: 2374-2383.
28. Riant E, Waget A, Cogo H, Arnal J, Burcelin R, et al. (2009) Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 150: 2109-2117.
29. Caraux G, Pinloche S, (2005) PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics 21: 1280-1281.
30. Langcake P, Pryce RJ, (1977) A new class of phytoalexins from grapevines. Experientia 33: 151-152.
31. Wang W, Lai H, Hsueh P, Chiou RY, Lin S, et al. (2006) Inhibition of swarming and virulence factor expression in Proteus mirabilis by resveratrol. J Med Microbiol 55: 1313-1321.
32. Chan MM, (2002) Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochem Pharmacol 63: 99-104.
33. Drucker DJ, (2002) Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122: 531-544.
34. Deacon CF, (2004) Circulation and degradation of GIP and GLP-1. Horm Metab Res 36: 761-765.
35. Nauck M, (1996) Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Diabet Med 13: S39-43.
36. Burcelin R, (2005) The incretins: a link between nutrients and well-being. Br J Nutr 93 (Suppl 1): S147-156.
37. Cani PD, Holst JJ, Drucker DJ, Delzenne NM, Thorens B, et al. (2007) GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Mol CellEndocrinol 276: 18-23.
38. Ahrén B, (2008) Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs 13: 593-607.
39. Dal-Pan A, Blanc S, Aujard F, (2010) Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol 10: 11.
40. Vitrac X, Desmoulière A, Brouillaud B, Krisa S, Deffieux G, et al. (2003) Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 72: 2219-2233.
41. Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, et al. (2010) Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J ClinNutr 91: 1590-1597.
42. Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, et al. (2006) Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 55: 1484-1490.
43. Putaala H, Salusjärvi T, Nordström M, Saarinen M, Ouwehand AC, et al. (2008) Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res Microbiol 159: 692-698.
44. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, et al. (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1: 6ra14.